Celldex Therapeutics Announces Upcoming Presentation at Oppenheimer
Oppenheimer Healthcare Conference 2012
NEEDHAM, Mass. -- December 07, 2012
Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today that Anthony
Marucci, President and Chief Executive Officer, is scheduled to present a
corporate overview at the Oppenheimer 23rd Annual Healthcare Conference on
Wednesday, December 12, 2012 at 10:00 am ET at the Waldorf=Astoria in New York
A live webcast of the presentation will be available online on the “Events &
Presentations” page of the “Investors & Media” section of the Celldex website.
A replay of the presentation will be available for 30 days following the
About Celldex Therapeutics, Inc.
Celldex Therapeutics is the first antibody-based combination immunotherapy
company. Celldex has a pipeline of drug candidates in development for the
treatment of cancer and other difficult-to-treat diseases based on its
antibody focused Precision Targeted Immunotherapy (PTI) Platform. The PTI
Platform is a complementary portfolio of monoclonal antibodies,
antibody-targeted vaccines and immunomodulators used in optimal combinations
to create novel disease-specific drug candidates. For more information, please
Celldex Therapeutics, Inc.
Sarah Cavanaugh, 781-433-3161
Vice President of IR & Corp Comm
Brad Miles, 646-513-3125
Press spacebar to pause and continue. Press esc to stop.